Cyclacel Pharmaceuticals Announces Multiple Clinical Abstracts Selected for Presentation at the ASH 2019 Annual Meeting
November 06 2019 - 9:00AM
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP)
("Cyclacel" or the "Company"), a biopharmaceutical company
developing innovative medicines based on cancer biology, announced
that data from Cyclacel’s CYC065 and sapacitabine ongoing clinical
studies have been selected for presentation at the 61st American
Society of Hematology Annual Meeting and Exposition (December 7-11)
in Orlando, Florida. The poster presentations will provide details
and updates for three clinical studies: CYC065 in combination with
venetoclax in patients with relapsed or refractory CLL, CYC065 in
combination with venetoclax in patients with relapsed or refractory
AML or MDS and sapacitabine in combination with venetoclax in
patients with relapsed or refractory AML or MDS. All three trials
are being conducted as part of Cyclacel’s collaboration with MD
Anderson Cancer Center.
Presentation details are as follows:
Title: A Phase I Study Combining CDK2/9 Inhibitor CYC065 with
Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory
Chronic Lymphocytic Leukemia (CLL)Presenter: Dr. William G.
WierdaSession Name: 642. CLL: Therapy, excluding Transplantation:
Poster IDate: Saturday, December 7, 2019 Presentation Time: 5:30 PM
- 7:30 PM Location: Orange County Convention Center, Hall
BPublication Number: 1761
Title: Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2
Inhibitor, to Treat Patients with Relapsed or Refractory AML or
MDSPresenter: Dr. Gautam BorthakurSession Name: 616. Acute Myeloid
Leukemia: Novel Therapy, excluding Transplantation: Poster IDate:
Saturday, December 7, 2019 Presentation Time: 5:30 PM - 7:30 PM
Location: Orange County Convention Center, Hall BPublication
Number: 1379
Title: An Oral Combination Study of Novel Nucleoside Analogue
Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with
Relapsed or Refractory AML or MDSPresenter: Dr. Tapan KadiaSession
Name: Acute Myeloid Leukemia: Novel Therapy, excluding
Transplantation: Poster IIIDate: Monday, December 9,
2019Presentation Time: 6:00 PM - 8:00 PM Location: Orange County
Convention Center, Hall BPublication Number: 3926
In addition researchers from Paul O'Gorman Leukaemia Research
Centre, Institute of Cancer Sciences, University of Glasgow,
Glasgow, United Kingdom led by Professor Mhairi Copeland will
present preclinical data on the combination of CY065 and
venetoclax.
Title: Combination of CYC065, a Second Generation CDK2/9
Inhibitor, with Venetoclax or Standard Chemotherapies – a Novel
Therapeutic Approach for Acute Myeloid Leukaemia (AML)Presenter:
Dr. Wittawat ChantkranSession Name: 616. Acute Myeloid Leukemia:
Novel Therapy, excluding Transplantation: Poster IIIDate: Monday,
December 9, 2019Presentation Time: 6:00 PM - 8:00 PM Location:
Orange County Convention Center, Hall BPublication Number: 3938
Abstracts for the 2019 ASH Annual Meeting can be accessed at:
https://www.hematology.org/Annual-Meeting/.
About Cyclacel Pharmaceuticals, Inc.Cyclacel
Pharmaceuticals is a clinical-stage biopharmaceutical company
developing innovative cancer medicines based on cell cycle,
transcriptional regulation and DNA damage response biology. The
transcriptional regulation program is evaluating CYC065 as a single
agent in solid tumors and in combination with venetoclax in
patients with relapsed or refractory CLL and AML/MDS. The DNA
damage response program is evaluating an oral combination regimen
of sapacitabine and venetoclax in patients with relapsed or
refractory AML/MDS. An IST is evaluating an oral combination
regimen of sapacitabine and olaparib in patients with BRCA mutant
breast cancer. The anti-mitotic program is evaluating CYC140, a
PLK1 inhibitor, in AML/MDS patients. Cyclacel's strategy is to
build a diversified biopharmaceutical business focused in
hematology and oncology based on a pipeline of novel drug
candidates. For additional information, please visit
www.cyclacel.com.
Forward-looking StatementsThis news release
contains certain forward-looking statements that involve risks and
uncertainties that could cause actual results to be materially
different from historical results or from any future results
expressed or implied by such forward-looking statements. Such
forward-looking statements include statements regarding, among
other things, the efficacy, safety and intended utilization of
Cyclacel's product candidates, the conduct and results of future
clinical trials, plans regarding regulatory filings, future
research and clinical trials and plans regarding partnering
activities. Factors that may cause actual results to differ
materially include the risk that product candidates that appeared
promising in early research and clinical trials do not demonstrate
safety and/or efficacy in larger-scale or later clinical trials,
trials may have difficulty enrolling, Cyclacel may not obtain
approval to market its product candidates, the risks associated
with reliance on outside financing to meet capital requirements,
and the risks associated with reliance on collaborative partners
for further clinical trials, development and commercialization of
product candidates. You are urged to consider statements that
include the words "may," "will," "would," "could," "should,"
"believes," "estimates," "projects," "potential," "expects,"
"plans," "anticipates," "intends," "continues," "forecast,"
"designed," "goal," or the negative of those words or other
comparable words to be uncertain and forward-looking. For a further
list and description of the risks and uncertainties the Company
faces, please refer to our most recent Annual Report on Form 10-K
and other periodic and other filings we file with the Securities
and Exchange Commission and are available at www.sec.gov. Such
forward-looking statements are current only as of the date they are
made, and we assume no obligation to update any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contacts
Company: |
Paul McBarron, (908) 517-7330, pmcbarron@cyclacel.com |
Investor Relations: |
Russo Partners LLC, Jan Medina, CFA, (646) 942-5632 |
|
Jan.Medina@russopartnersllc.com |
© Copyright 2019 Cyclacel Pharmaceuticals, Inc. All Rights
Reserved. The Cyclacel logo and Cyclacel® are trademarks of
Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Historical Stock Chart
From Sep 2023 to Sep 2024